ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

VESICARE
Overactive bladder/enuresis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

VESICARE Rx

Generic Name and Formulations:
Solifenacin succinate 5mg, 10mg; tabs.

Company:
Astellas Pharma US, Inc.

Therapeutic Use:

Indications for VESICARE:

Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Adult:

Swallow whole with water. Initially 5mg once daily; if well tolerated, may increase to 10mg once daily. Severe renal impairment (CrCl<30mL/min), moderate hepatic impairment (Child-Pugh B), or concomitant potent CYP3A4 inhibitors: max 5mg once daily.

Children:

Not established.

Contraindications:

Gastric or urinary retention. Uncontrolled narrow-angle glaucoma.

Warnings/Precautions:

Severe hepatic impairment: not recommended. Bladder outflow obstruction. Decreased GI motility. Controlled narrow-angle glaucoma. History of QT prolongation. Monitor for CNS effects esp. after initiation or dose increases; consider reducing dose or discontinue if occurs. Renal or hepatic impairment. Exposure to high environmental temperature. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Pharmacological Class:

Muscarinic antagonist.

Interactions:

Potentiated by potent CYP3A4 inhibitors (eg, ketoconazole); see Adult. May be antagonized by CYP3A4 inducers. Avoid drugs known to prolong the QT interval. Additive anticholinergic effects with other anticholinergics.

Adverse Reactions:

Dry mouth, constipation, UTI, blurred vision; angioedema (discontinue if occurs), CNS effects (eg, headache, confusion, hallucination, somnolence); rare: anaphylactic reactions.

Metabolism:

Hepatic (CYP3A4). 98% protein bound.

Elimination:

Renal (major), fecal (minor).

Generic Availability:

NO

How Supplied:

Tabs—30, 90

Sign Up for Free e-Newsletters